ASH 2020 | MRD: Paving the way for future clinical trials in myeloma
Francesca Gay
• 14 Dec 2020
Francesca Gay, MD, PhD, University of Turin, Turin, Italy, highlights the importance of using measurable residual disease (MRD) measurements as predictors of outcomes in newly diagnosed multiple myeloma. She discusses how MRD should be utilized in clinical trials to modulate treatment according to MRD status in the near future. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
